TWiV 1353: Phage bet-hedging and EBV antibodies
TWiV explores how bacteriophages enable bet-hedge against bacterial immune defenses, and how transgenic mice engineered to produce human antibodies yielded potent anti-EBV candidates targeting gp350 and gp42, a promising step toward Epstein-Barr therapeutics. Hosts: Vincent Racaniello, Rich Condit, Brianne Barker, and…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from This Week in Virology
See all episodes →One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.